Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(29%)
Results Posted
200%(4 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
3
43%
Ph phase_2
4
57%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Terminated(3)

Detailed Status

Completed2
Terminated2
Withdrawn1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 24 (57.1%)

Trials by Status

withdrawn114%
completed229%
terminated229%
active_not_recruiting114%
recruiting114%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_2

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

NCT06014255
terminatedphase_1

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT05708924
active_not_recruitingphase_2

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

NCT02923180
terminatedphase_2

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

NCT04634825
completedphase_1

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

NCT04630769
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06014255Phase 2

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Recruiting
NCT05708924Phase 1

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Terminated
NCT02923180Phase 2

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Active Not Recruiting
NCT04634825Phase 2

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Terminated
NCT04630769Phase 1

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

Completed
NCT02982941Phase 1

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Completed
NCT04129320Phase 2

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7